Decreasing the Use of Prescription Opiates and Benzodiazepines Among Individuals Enrolled in Methadone Programs Kim Castelnovo, RPh Pharmacy Manager, Community Care © 2014 Community Care Behavioral Health Organization
Dec 14, 2015
Decreasing the Use of Prescription Opiates and Benzodiazepines Among Individuals Enrolled in Methadone
ProgramsKim Castelnovo, RPh
Pharmacy Manager, Community Care
© 2014 Community Care Behavioral Health Organization
About Community Care
• Behavioral Health Managed Care Company
• Founded in 1996
• Statewide HealthChoices presence; 39 of 67 Pennsylvania counties
• 10 offices across the Commonwealth
• Over 600 employees
2© 2014 Community Care Behavioral Health Organization
About Community Care
• Medicaid/HealthChoices membership: 725,000
• Commercial/Medicare membership: 450,000
• Approximately 110,000 people served annually
• Statewide network of approximately 1,600 providers 3© 2014 Community Care Behavioral Health Organization
4
Serving 39 Counties
© 2014 Community Care Behavioral Health Organization
Community Care Office
Pike
Erie
Crawford
Mercer
Venango
LawrenceButler
Beaver
Washington
Armstrong
Indiana
Westmoreland
Allegheny
Greene
FayetteSomerset
CambriaBlair
Delaware
Clarion
Forest
Warren McKean Potter
CameronElk
Jefferson
Clearfield
Bedford
Centre
Clinton
Fulton Franklin
Adams
Cumberland
Perry
MifflinSnyder
Union
Lycoming
Tioga Bradford
ColumbiaMontour
Northumberland
Dauphin
York
Lancaster
Chester
Berks Lebanon
Schuylkill
Montgomery
Philadelphia
Juniata
Sullivan
HuntingdonBucks
LehighNorthampton
Carbon
Monroe
Pike
Luzerne
WyomingLackawanna
Susquehanna
Wayne
Overview
• Opiate and benzodiazepine use in individuals in methadone programs
– With overdose deaths from heroin and prescription pain medications increasing in the U.S., opioid addiction is an important concern for Medicaid programs
– Medicaid beneficiaries have higher rates of opioid addiction than other insured groups 5© 2014 Community Care Behavioral Health Organization
Benzodiazepine Use and Misuse
• Among patients in a methadone program – BMC Psychiatry, May 2011:
– Benzodiazepines (BZD) misuse and abuse is a serious public health problem in the U.S.
– This problem is especially pertinent among those with opiate dependence because these individuals are more likely to experience elevated anxiety after stopping use of opiates
– It has been shown that individuals who abuse BZD are at increased risk of continuing opiate abuse and failing to stay in methadone treatment
6© 2014 Community Care Behavioral Health Organization
Benzodiazepine Use and Misuse
• In a Baltimore methadone program:– Survey conducted at a methadone
treatment program in Baltimore– 194 questionnaires were included in the
final data analysis• 47% reported using BZD with/without
a prescription• 25% said that their initial use began with
a prescription• 54% did not start using BZD until after
entering the methadone program
7© 2014 Community Care Behavioral Health Organization
Benzodiazepine Use and Misuse
• Among patients in a methadone program the main reasons given for using BZD without a prescription:– Curiosity– To relieve tension or anxiety– To feel good– To get high– To overcome depression or frustration
8© 2014 Community Care Behavioral Health Organization
Benzodiazepine Use and Misuse
• When asked patients in a methadone program if they would consider reducing or stopping the use of BZD if the methadone program could provide help that would work:– 40% said “Yes, definitely”– 7% said “Maybe” – 19% said “No” – 33% had already stopped using BZD
9© 2014 Community Care Behavioral Health Organization
Benzodiazepine Use
• Among Community Care Medicaid enrollees: – Analysis includes data for 39
Community Care counties
– Number of unique members per year filling benzodiazepines
– Benzodiazepine use very low among children and adolescents
– Adult benzodiazepine Use ranges from 13-24% of Medicaid enrollment among Community Care counties
10© 2014 Community Care Behavioral Health Organization
Opiate Use
• Among Community Care Medicaid enrollees:– Analysis includes data for 39
Community Care counties
– Number of unique members per year filling four or more opiate scripts
– Opiate use very low among children and adolescents
– Adult opiate use ranges from 11-21% of Medicaid enrollment among Community
Care counties
11© 2014 Community Care Behavioral Health Organization
Community Care Methadone Provider Initiative
A Quality Improvement Initiative Between Counties, Methadone Providers, and Community Care
© 2014 Community Care Behavioral Health Organization
Objective
• To identify members enrolled in methadone treatment programs who are concurrently filling benzodiazepine and /or opiate prescriptions
• Collaborate with methadone providers to reduce the incidence of concurrent utilization and ultimately improve care
13© 2014 Community Care Behavioral Health Organization
Intervention
• Community Care generates member reports on a monthly basis and sends to the methadone providers in Allegheny County
• Member report includes medications filled and prescriber information
• Methadone provider uses the information to help address any clinical issues with the member
14© 2014 Community Care Behavioral Health Organization
15
Frequency of Benzodiazepine Use
Frequency of benzodiazepine use among members in methadone programs in Allegheny County
Time period# of members in methadone for at least 10 days (den)
# of members with at least 10 days of methadone + 1 Rx of Benzo (num)
Percent (num/den)
2009-Q4 1462 524 35.8%
2010-Q2 1424 509 35.7%
2010-Q4 1463 536 36.6%
2011-Q2 1473 486 33.0%
2011-Q4 1512 503 33.3%
2012-Q2 1529 502 32.8%
2012-Q4 1523 469 30.8%
2013-Q2 1516 424 28.0%
2013-Q4 1479 384 26.0%
© 2014 Community Care Behavioral Health Organization
16
Frequency of Opiate Use
Frequency of opiate use among members in methadone programs in Allegheny County
Time period# of members in methadone for at least 10 days (den)
# of members with at least 10 days of methadone + 1 Rx of opiate (num)
Percent (num/den)
2009-Q4 1462 436 29.8%
2010-Q2 1424 377 26.5%
2010-Q4 1463 387 26.5%
2011-Q2 1473 381 25.9%
2011-Q4 1512 348 23.0%
2012-Q2 1529 377 24.7%
2012-Q4 1523 328 21.5%
2013-Q2 1516 267 17.6%
2013-Q4 1479 262 17.7%
© 2014 Community Care Behavioral Health Organization
17
Assessing Impact of Interventions
• Members with at least 10 days of Methadone Claims = 636
© 2014 Community Care Behavioral Health Organization
60.20%17.80%
22.00%
Pre Intervention Metrics May-June 2012 (N = 636)
B only B + O O only
18
Assessing Impact of Interventions
• Members with at least 10 days of Methadone Claims = 485
© 2014 Community Care Behavioral Health Organization
40.60%
11.30%7.40%
40.60%
Post Intervention Metrics May-June 2013 (N = 485)
B only B + OO only No B + No O
19
Comparison
Pre-Period(May-June
2012)
Post-Period(May-June
2013)
Members on Benzodiazepines Only 60.2% 40.6%
Members on Opiates Only 22.0% 7.4%
Members on Both Medications 17.8% 11.3%
Members on No Medications 40.6%
© 2014 Community Care Behavioral Health Organization
Conclusions
• The decrease in concurrent medication over the past four years is encouraging
• Provider feedback has been very positive about this initiative
• Providers have adopted new policies when caring for individuals on concurrent benzodiazepines or opiates to ensure appropriate use
20© 2014 Community Care Behavioral Health Organization
Collaboration of Care Implementation Guideline
Presented by:Sara Remaley, MSPC, CAADC, Clinical Supervisor WPIC NATP
Valerie Gualazzi, MS, CADC, Program Director WPIC NATPWestern Psychiatric Institute and Clinic
• WPIC NATP is a clinic specializing in opioid dependency in
addition to psychiatric comorbidity.
• WPIC offers methadone maintenance treamtent, suboxone
treatment, psychiatric care and medication management,
mental health, and addiction therapy.
• WPIC currently treats approximately 420 patients on a
regular basis.
Western Psychiatric Institute and Clinic
Narcotic Addiction Treatment Program (NATP) -Addiction Medicine Services
22
Rationale
• NATP recognized a need to address the misuse and abuse of prescription benzodiazepines by patients enrolled in medication assisted treatment.
• High rates of patients were enrolling in treatment and concurrently becoming addicted to and abusing benzodiazepines, posing health risks, adverse effects, and ultimately untimely discharge from treatment.
Collaboration of Care
• 2012- WPIC NATP redesigned the program’s philosophy and position regarding concurrent use and abuse of prescription benzodiazepines and opiates while taking methadone.
• Contraindications and potential for adverse effects helped NATP move in the direction of ‘therapeutic no tolerance’.
• The “Collaboration of Care” Procedure : indicating NATP’s willingness to work with patients currently on prescription benzodiazepines to taper off and receive evidence based interventions and seek alternative treatment options as needed.
Collaboration of Care
• The Collaboration of Care Procedure was developed as a way to inform patients of the new treatment philosophy indicating: use of benzodiazepines and opiates while on methadone is no longer permissible.
• With the understanding that tapering from these type of medication can be a difficult and lengthy process with potential for relapse, NATP developed a procedural guideline to assist both patients and staff through this new process.
• Difficult tapering process, risk related to withdrawal symptoms, and potential need for medically supervised detoxification.
• High Relapse rates with benzodiazepines.• Concurrent rates of psychiatric comorbidity and the
need to address/treat underlying mental health conditions.
• Collaborating with providers (prescribing physicians) vs. illicit street use.
• Addressing diversion…How does this fit?
Barriers to addressing bzd use:
27
• Step 1: Staff Education– Development of Procedural Guideline highlighting
philosophy, procedures and interventions, and processes for team to follow.
• Step 2: Patient Education– An FAQ was developed and handed out to all patients
indicating the new Collaboration of Care and Program Philosophy regarding Concurrent use of benzodiazepines while in treatment.
Let the collaboration begin….
28
• Step 3: Patient Acknowledgement and Responsibilities:– Reviewing the new philosophy and Collaboration of Care with
patients, and asking them to acknowledge with their signatures that they have been informed.
– A part of this process is also to explain to patients, the risks, as well as their rights. Albeit patients may reserve the right to refuse collaboration, they are also informed how this may directly impact their ability to remain in treatment.
• Step 4: Interventions– Once the Collaboration of Care is initiated, the following
procedures /interventions may be followed:• Urine Drug Screens and CCBHO Report reviewed.• Contact with the prescribing physician (physician to
physician) to discuss recommendations and to create a tapering regimen.
– Pill Counts
• Illicit Street Use: Assessing need for medically supervised detoxification. Resources: Mercy Hospital Emergency Room, WPIC DEC (Diagnostic Evaluation Center).
• UDS Confirmatory tests to determine if “levels” are decreasing- indicating progress/regression.
• Interventions Continued:• Assessing underlying mental health and psychiatric disorders such
as anxiety, depression, mood disorder, bipolar disorder, etc. Choosing a modality to effectively work with and treat these disorders in addition to addiction.
– CBT, REBT, Gestalt Therapy, DBT, Motivational Interviewing, Person Centered etc.
• Modifying treatment plans: Increasing therapy, regular appointments with Psychiatrist, following a medication regimen, ongoing collaboration.
• Maintaining focus on individualized care through individualized recommendations. Assessing Progress: How is this done? Regular team meetings and supervision.
Response to Interventions
• What happened after the Collaboration of Care was initiated?– NATP experienced responses similarly associated with the Change
Curve (Kubhler-Ross) • Shock, Denial, Anger, Acceptance, Integration
• How long did it take before a change was noticeable?– Integration took time and CONSISTENCY IS KEY
• Response to change implementation included:– Compliance and Collaboration.– Increase in individual/group therapy- engagement in regular
psychotherapy.– Increase in psychiatric treatment and psychopharmacology.– Exacerbation of symptoms/negative behaviors.– Increase in referrals to Higher LOC’s. – Decrease in bzd rates.– Increase in compliance/privilege status.
Response to Interventions
34
• Establishing pre and post intervention baselines:– Rates of bzd use/abuse among patients.– Urine Drug Screen Results (including break-down of levels)– Individualized Progress– Relapse rates– Decrease in attaining prescriptions.– Patient Discharges– Sustained abstinence
Evaluating Effectiveness
35
• Addressing concurrent use/abuse of benzodiazepines through the following steps:– Develop Program Philosophy– Identify Perceived Barriers– Education Staff– Educate Patients– Identify intervention strategies and evidenced based practices– Identify pre and post intervention baseline data
Summary
36
“Meeting Needs …..Renewing Life”
Timothy H. Reese, M.D., MRO, SAPMedical Director 1425 Beaver AvenuePittsburgh, PA 15233Phone: 412-322-8415 Ext. 109Fax: 412-322-9224/421-322-3352
“Decreasing the use of prescription opiates and benzodiazepines among individualsEnrolled in methadone programs”
HISTORY OF TADISO
ESTABLISHED IN 1968 AS NON-PROFIT
700 PATIENTS—24 FULL TIME COUNSELORS—1 MEDICAL DIRECTOR1 PA.
POPULATION: 2/3 NON-HISPANIC WHITE AND 1/3 AFRO-AMERICAN AND OTHER
DEMOGRAPHICS
NON-HISPANIC WHITES 20-44 YEARS…….FASTEST
NON-HISPANIC WHITES 20-34 YEARS………FASTEST OF THE FAST
NON-HISPANIC WHITES 20-34 YEARS………SHOOTING MORE
NON-HISPANIC WHITES 20-44 YEARS……….INHALING MORE
PENNSYLVANIA
2008-2012 PERSONS ENROLLED IN SUBSTANCE ABUSE TREATMENT PROGRAMS WHICH PRESCRIBED METHADONE INCREASED 18.9%
MESSAGE
WE ARE IN THE MIDST OF AN EPIDEMIC OF OPIOID ADDICTION AND ITS DEVASTATING TOLL ON SOCIETY!
METHADONE IS AND CAN BE AN EVEN GREATER PART OF OUR ARSENAL AGAINST THIS DEADLY FOE!
PATHOPHYSIOLOGYOF
OPIOID ADDICTION
--MEDULLA LOCUS CAERULEUS---90% OF CATECHOLAMINES IN CNS
--RESPONSIBLE FOR THE VEGETATIVE FUNCTIONS OF THE ORGANISM (SUPPORT LIFE)
--THERMOSTAT ANALOGY AND THE OPIOID WITHDRAWAL SYNDROME
CLINICAL MANIFESTATIONSOF
OPIOID WITHDRAWAL
CENTRAL NERVOUS SYSTEM:
RESTLESSNESSIRRITABILITYINSOMNIACRAVINGYAWNING
CLINICAL MANIFESTATIONSOF
OPIOID WITHDRAWAL
MUCOCTANEOUS: RHINORRHEA
EYES: LACRIMATION PUPIL DILATION
SKIN: PILOERECTION (GOOSEFLESH)
CLINICAL MANIFESTATIONSOF
OPIOID WITHDRAWAL
I. PSYCHOSOMATIC WITHDRAWAL?
II. PSEUDO-WITHDRAWAL?
III. REAL WITHDRAWAL?
DOPAMINE
----VTA/NUCLEUS ACCUMBENS (FOREBRAIN)
DRUG ABUSE DUMPS MASSIVE AMOUNTS OF DOPAMINE INTO THIS AREA.
REINFORCES BEHAVIOUR THAT IS PARAMOUNT TO SURVIVAL OF THE SPECIES
UP-REGULATIONOF
DOPANINERGIC NEURONS
--AFTER REPEATED EXPOSURE (DRUG ABUSE) TO THESE MASSIVE AMOUNTS
OF DOPAMINE THE TARGET NEURONS BECOME PROGRESSIVELY LESS
RESPONSIVE! NET RESULT MORE STIMULATION GIVE LESS RESPONSE THUS
PROPELLING THE ADDICTION PROCESS!
BENZODIAZEPINES
INTERNEURONS IN THE VTA APPLY INHIBITORY EFFECTS ON DOPAMINERGIC NEURONS
THESE INHIBITORY INTERNEURONS EXERT THEIR EFFECT ON THE DOPAMINERGIC NEURONS BY WAY OF GABA (GAMMA AMINO BUTYRIC ACID)
BENZODIAZEPINES INHIBIT THIS INHIBITORY EFFECT. THIS INHIBITION RESULTS IN A MASSIVE RELEASE OF DOPAMINE FROM THE DOPAMINERGIC NEURONS.
THIS IS THE SYNERGISM WHICH OCCURS WHEN BENZODIAZEPINES ARE GIVEN WITH AN OPIOID; E.G., METHADONE.
OPIOIDS
IN A STABILIZED METHADONE PATIENT ANY ADDITIONAL OPIOID WILL CAUSE DESTABLIZATION ;
IF THE OPIOIDS ARE TAKEN TO AN ANALGESIC LEVEL ONLY THE DESTABILIZATION WILL MAINLY AFFECT THE MEDULLA LOCUS CAERULEUS.
IF THE OPIOIDS ARE TAKEN TO THE EUPHORIC LEVEL THE DESTABILIZATION WILL AFFECT THE DOPAMINERGIC NEURONS AS WELL.
CLONIDINEIN
SEARCH OF DOPAMINE
SINCE THE OPIOID WITHDRAWAL SYNDROME IS DUE IN PART TO HYPERACTIVITY OF THE MEDULLA LOCUS CAERULEUS AND EXCESSIVE CATECHOLAMINES, A DRUG WHICH BLOCKS THIS EFFECT SHOULD TREAT THIS PART OF THE OPIOID WITHDRAWAL SYNDROME.
CLONIDINE( CATAPRESS) IS A CENTRALLY ACTING ALPHA-2 BLOCKER AND DOES THIS WELL.
WHAT ABOUT THE DOPAMINE DEFICIENCY? A BENZODIAZEPINE WAS NEEDED TO BE ADDED TO THE ABOVE REGIMEN TO MAKE THE TREATMENT PALABLE TO THE PATIENT. THIS BENZODIAZEPINE VIA INHIBITING GABA IN INTERNEURONS OF THE VTA SUPPLIED THE DOPAMINE.
REPRESENTATIVE VIGNETTES
A. DR. COMPLETELY COOPERATIVE—MOST COMMON SCENARIO
B. DR. COOPERATIVE BUT DILATORY---NEEDS SOME PRODING
C. DR. COOPERATIVE BUT SELECTIVE---”NOT TO YOUR PATIENT”
D. DR. COOPERTIVE BUT NOT REALLY---REDUCE BUT WON’T STOP!
CCBHO INITIATIVE
THE EXPRESSED PURPOSE OF THIS INITIATIVE WAS TO DECREASE THE USE OF BENZODIAZEPINES AND OPIOIDS IN METHADONE CENTERS….AND IT WORKED!
CCBHO GIVES THE METHADONE CLINICS A LISTING OF PATIENTS WHO ARE GETTING BENZODIAZEPINE AND/OR OPIOID SCRIPTS. THESE PRESCRIPTIONS WOULD NOT BE REGISTERED AT THE CLINIC NOR WOULD EVIDENCE OF THE DRUGS SHOW IN THE ROUTINE URINES.
CCBHO INITIATIVE
THIS SCENARIO WAS VIRTUALLY UNCHANGED. DOCTOR TO DOCTOR COMMUNICATION SPOILED THE ENTERPRISE.